Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Nelfinavir is an HIV protease inhibitor, substrate of the transporter P-glycoprotein and metabolized via CYP2C19, CYP3A4 and CYP3A5 enzymes. * Pharmacokinetic studies have shown wide interindividual variability of nelfinavir concentrations, some of this variability perhaps caused by variant drug metabolism or transporter genes. * For CYP3A4*1B and CYP3A5*3 polymorphism, results from three studies are in agreement, showing no difference in nelfinavir concentrations between patients with these different genotypes. * However, for MDR1 and CYP2C19 polymorphism, there have been contradictory studies, showing either no impact on nelfinavir concentration or modified concentrations which could influence virological response. WHAT THIS STUDY ADDS * Patients with an *1/*2 or *2/*2 genotype for CYP2C19 had a nelfinavir to M8 biotransformation divided by 2 compared with *1/*1 patients. * No evidence of any influence of MDR1 polymorphism on nelfinavir absorption could be detected. AIMS To evaluate the effect of CYP2C19 polymorphism on nelfinavir and M8 pharmacokinetic variability in human immunodeficiency virus-infected patients and to study the link between pharmacokinetic exposure and short-term efficacy and toxicity. METHODS Nelfinavir (n = 120) and M8 (n = 119) concentrations were measured in 34 protease inhibitor-naive patients. Two weeks after initiating the treatment, blood samples were taken before, 1, 3 and 6 h after drug administration. Genotyping for CYP3A4, 3A5, 2C19 and MDR1 was performed. A population pharmacokinetic model was developed to describe nelfinavir-M8 concentration time-courses and to estimate interpatient variability. The influence of individual characteristics and genotypes were tested using a likelihood ratio test. Estimated mean (C(mean)), maximal (C(max)) and trough (C(trough)) nelfinavir and M8 concentrations were correlated to short-term virological efficacy and tolerance using Spearman nonparametric correlation tests. RESULTS A one-compartment model with first-order absorption, elimination and metabolism to M8 best described nelfinavir data. M8 was modelled by an additional compartment. Mean pharmacokinetic estimates and the corresponding intersubject variabilities were: absorption rate 0.17 h(-1) (99%), absorption lag time 0.82 h, apparent nelfinavir total clearance 52 l h(-1) (49%), apparent nelfinavir volume of distribution 191 l, M8 elimination rate constant 1.76 h(-1) and nelfinavir to M8 0.39 h(-1) (59%) in *1/*1 patients and 0.20 h(-1) in *1/*2 or *2/*2 patients for CYP2C19*2. Nelfinavir C(mean) was positively correlated to glycaemia and triglyceride increases (P = 0.02 and P = 0.04, respectively). CONCLUSIONS The rate of metabolism of nelfinavir to M8 was reduced by 50% in patients with *1/*2 or *2/*2 genotype for CYP2C19 compared with those with *1/*1 genotype.

[1]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[2]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[3]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[4]  M. Dudley,et al.  A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial , 2000, Antimicrobial Agents and Chemotherapy.

[5]  F. Goldwasser,et al.  Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.

[6]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[7]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[8]  S. Urien,et al.  Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 Women , 2006, Antimicrobial Agents and Chemotherapy.

[9]  J W Mulder,et al.  The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy , 1998, AIDS.

[10]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[11]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[12]  S. Spector,et al.  An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.

[13]  D. Burger,et al.  The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. , 2006, British journal of clinical pharmacology.

[14]  H. Dienemann,et al.  The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. , 2003, Pharmacogenetics.

[15]  S. Urien,et al.  Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children , 2006, Antimicrobial Agents and Chemotherapy.

[16]  F Mentré,et al.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. , 2005, British journal of clinical pharmacology.

[17]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[18]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[19]  M. Saag,et al.  Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.

[20]  A. Patick,et al.  Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities , 2001, Antimicrobial Agents and Chemotherapy.

[21]  P. Oxley,et al.  Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. , 2005, International journal of clinical pharmacology and therapeutics.

[22]  H. Schuitemaker,et al.  Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study , 2000, AIDS.

[23]  M. Hirsch,et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.